Cholera vaccine inactivated oral - International Vaccine Institute

Drug Profile

Cholera vaccine inactivated oral - International Vaccine Institute

Alternative Names: Euvichol; ShanChol

Latest Information Update: 15 Nov 2016

Price : $50

At a glance

  • Originator International Vaccine Institute
  • Developer EuBiologics; Incepta Vaccine; International Centre for Diarrhoeal Disease Research; International Vaccine Institute; Shantha Biotechnics
  • Class Cholera vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cholera

Most Recent Events

  • 28 Oct 2016 Cholvax® is still in clinical trials for Cholera in South Korea (International Vaccine Institute website, October 2016)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Cholera(Prevention) in South Korea (PO, Suspension)
  • 01 Jul 2016 Sanofi completes a phase-III trial in Cholera (Prevention, In infants, In children, In adolescents, In adults, In the elderly) in Dominican Republic (NCT02434822)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top